'What Ifs' for America's Research Consortia

Perhaps at no time since the Second World War has there been such an emphasis on the rapid transfer of research findings to development. The 1980s have seen the birth of dozens of research consortia designed to quicken the pace of technological development in the United States. Coming from a wide array of businesses and varied academic institutions, these R&D consortia are seen by many as the answer to the United States' regaining the lead it has lost in technological competitiveness. In The New

Written byDan Dimancescu
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

What are the prospects? Marc Tucker [director of the Carnegie Forum in Washington, D.C.] views the advent of research and development consortia with a cool dose of practicality. "If you were to look at these consortia as the principal instrument for adjusting to the problems that we face economically, I would have to say: 'Ridiculous.' They don't begin to get at the larger problems that we face. On their own terms, though, they are incredibly valuable contributions." His observation opens the question of whether the scale of the response represented by industry-university consortia is commensurate with the sense of threat to survival felt by American industry.

The first answer, then, to the "what if' question is that more consortia, properly capitalized and led, could well serve to accelerate the move toward a national technology agenda. This raises immediate questions of national policy. Should the federal government—following the recent lead of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies